Pivotal readout
Seladelpar normalizes ALP in most PBC patients in phase 3 IDEAL trial
Gilead reported that 75.4% of people taking Livdelzi reached the week-52 composite of normal alkaline phosphatase plus a 15% drop, against 16.1% on placebo, in a 96-person trial. Participants had primary biliary cholangitis with only mildly raised ALP despite or without tolerating ursodeoxycholic acid. No new safety signals emerged; regulators will be consulted.
Written by Gosset from public sources. Source types: Press release. Sources are available to Gosset users. Log in to see them.